CASTLE BIOSCIENCES INC (CSTL) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 11 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | after close | 30 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | after close | 34 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | after close | 35 | 8-K |
| Q1 FY2025 | Mon, May 5, 2025 | after close | 35 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Castle Biosciences Reports Third Quarter 2026 Results Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas – November 5, 2026 – Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, " exhibit |
| Q3 FY2026 | "Cash, Cash Equivalents and Marketable Investment Securities As of Sep. 30, 2026, the Company’s cash, cash equivalents and marketable investment securities totaled $277.7 million. 2026 Outlook Castle Biosciences is raising its guidance for anticipated total revenue i n 2026." exhibit |
| Q3 FY2026 | "The Company now anticipates generating between $385-395 million in total revenue in 2026, compared to the previously provided guidance of between $365-375 million." exhibit |
| Q3 FY2026 | "An archive of the webcast will be available on the Company’s website until November 26, 2026." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to $365-375 million from $345-355 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas – July 30, 2026 – Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter ended " exhibit |
| Q2 FY2026 | "“Given this momentum, we are raising our 2026 total revenue guidance to $365-375 million, up from our previous range of $345-355 million." exhibit Read from the sentence: revenue $365 million to $375 million, FY2026 |
| Q2 FY2026 | "We also now expect to achieve positive Adjusted EBITDA for the third quarter, the fourth quarter and the full year 2026." exhibit |
| Q2 FY2026 | "Cash, Cash Equivalents and Marketable Investment Securities As of Jun. 30, 2026, the Company’s cash, cash equivalents and marketable investment securities totaled $266.8 million. 2026 Outlook Castle Biosciences is raising its guidance for anticipated total revenue i n 2026." exhibit |
| Q2 FY2026 | "The Company now anticipates generating between $365-375 million in total revenue in 2026, compared to the previously provided guidance of between $345-355 million." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CSTL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CSTL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CSTL/"><img src="https://veritasdata.dev/embed/CSTL.svg" alt="CSTL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CSTL/)
Script
<script async src="https://veritasdata.dev/embed/CSTL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CSTL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.